Browse > Article
http://dx.doi.org/10.1016/j.jgr.2018.12.012

Medicinal potential of Panax ginseng and its ginsenosides in atopic dermatitis treatment  

Lorz, Laura Rojas (Department of Integrative Biotechnology, Sungkyunkwan University)
Kim, Mi-Yeon (School of Systems Biomedical Science, Soongsil University)
Cho, Jae Youl (Department of Integrative Biotechnology, Sungkyunkwan University)
Publication Information
Journal of Ginseng Research / v.44, no.1, 2020 , pp. 8-13 More about this Journal
Abstract
Atopic dermatitis (AD) is a chronic and relapsing inflammatory disease that affects 1%-20% of people worldwide. Despite affecting many people, AD current treatments, such as corticosteroids and calcineurin inhibitors, have not only harmful secondary effects but are also often ineffective. Therefore, natural nontoxic compounds are on high demand for developing new effective AD treatments. Panax ginseng Meyer has been used traditionally for its promising healing and restorative properties to treat many diseases including skin disorders, reason why in this review we want to explore the research performed with AD and P. ginseng as well as determining its potential for new drug development. Previous researches have shown that P. ginseng has positive effects in AD patients such as lower eczema area and severity index, transepidermal water loss, and immunoglobulin E levels and better quality of sleep. In vivo animal models, as well, have shown positive results to P. ginseng and derived ginsenosides, such as the decrease of transepidermal water loss, immunoglobulin E levels in serum, allergy-related cytokines, and downregulation of NF-κB, MAPK, and Ikaros pathways. All of these previous data suggest that P. ginseng and its derived ginsenosides are undoubtedly a nontoxic effective option to treat AD.
Keywords
Alternative medicine; Atopic dermatitis; Filaggrin; Ginsenosides; Panax ginseng;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. Allergy Asthma Immunol Res 2016;8:181-90.   DOI
2 Kim EH, Kim W. An insight into ginsenoside metabolite compound K as a potential tool for skin disorder. Evidence-based complementary and alternative medicine. eCAM 2018;2018. 8075870-8075870.
3 Sarvenaz S-R, Sara S-R, Amirhossein S, Zahra T-N. Ginseng in dermatology: a review. Cur Pharmaceut Des 2017;23:1649-66.   DOI
4 Kim H, Park CW, Cho SH. The beneficial effect of Korean red ginseng extract on atopic dermatitis patients: an 8 weeks open, noncomparative clinical study. Ann Dermatol 2018;30:304-8.   DOI
5 Lee KG, Son SW. Efficacy of korean red ginseng in the treatment of atopic dermatitis. J Ginseng Res 2011;35:149-54.   DOI
6 Cho E, Cho SH. Effects of Korean red ginseng extract on the prevention of atopic dermatitis and its mechanism on early lesions in a murine model. J Ethnopharmacol 2013;145:294-302.   DOI
7 Lee HJ, Cho SH. Therapeutic effects of Korean red ginseng extract in a murine model of atopic dermatitis: anti-pruritic and anti-inflammatory mechanism. J Kor Med Sci 2017;32:679-87.   DOI
8 Samukawa K, Izumi Y, Shiota M, Nakao T, Osada-Oka M, Miura K, Iwao H. Red ginseng inhibits scratching behavior associated with atopic dermatitis in experimental animal models. J Pharmacol Sci 2012;118:391-400.   DOI
9 Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase three. J Allergy Clin Immunol 2009;124. 1251-1258.e1223.   DOI
10 Choi JH, Jin SW, Park BH, Kim HG, Khanal T, Han HJ, Hwang YP, Choi JM, Chung YC, Hwang SK, et al. Cultivated ginseng inhibits 2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice and $TNF-{\alpha}/IFN-{\gamma}-induced$ TARC activation in HaCaT cells. Food Chem Toxicol 2013;56:195-203.   DOI
11 Lee B-H, Kim H-K, Jang M, Kim H-J, Choi S-H, Hwang S-H, Kim H-C, Rhim H, Cho I-H, Nah S-Y. Effects of gintonin-enriched fraction in an atopic dermatitis animal model: involvement of autotaxin regulation. Biol Pharmaceut Bull 2017;40:1063-70.   DOI
12 Nowicki R, Nowicki R, Trzeciak M, Wilkowska A, sokolowska-wojdylo M, Lugowska-Umer H, Baranska-Rybak W, Kaczmarski M, Kowalewski C, Kruszewski J, et al. Special paper atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section. Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology; 2015.
13 Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, Guttman-Yassky E, Paller AS, Pariser D, Silverberg JI, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol 2017;5:1519-31.   DOI
14 Park HJ, Kim DH, Park SJ, Kim JM, Ryu JH. Ginseng in traditional herbal prescriptions. J Ginseng Res 2012;36:225-41.   DOI
15 Kimura Y, Sumiyoshi M, Sakanaka M. Effects of ginsenoside $Rb_{1}$ on skin changes. J Biomed Biotechnol 2012;2012. 946242-946242.
16 Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy 2013;68:974-82.   DOI
17 Egawa G, Kabashima K. Barrier dysfunction in the skin allergy. Allergol Int 2018;67:3-11.   DOI
18 Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2011;2:110.
19 Osada-Oka M, Hirai S, Izumi Y, Misumi K, Samukawa K, Tomita S, Miura K, Minamiyama Y, Iwao H. Red ginseng extracts attenuate skin inflammation in atopic dermatitis through p70 ribosomal protein S6 kinase activation. J Pharmacol Sci 2018;136:9-15.   DOI
20 Kim JR, Choi J, Kim J, Kim H, Kang H, Kim EH, Chang J-H, Kim Y-E, Choi YJ, Lee KW, et al. 20-O-${\beta}$-d-glucopyranosyl-20(S)-protopanaxadiol-fortified ginseng extract attenuates the development of atopic dermatitis-like symptoms in NC/Nga mice. J Ethnopharmacol 2014;151:365-71.   DOI
21 Wang H-H, Li Y-C, Huang Y-C. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2016;138. 1719-1722.e1711.   DOI
22 McPherson T. Current understanding in pathogenesis of atopic dermatitis. Indian J Dermatol 2016;61:649-55.   DOI
23 Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Plotz S, Knol EF, Kapp A, et al. Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693-6.   DOI
24 Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy 2018;73:29-36.   DOI
25 Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy 2014;2014. 354250-354250.   DOI
26 Cesare AD, Meglio PD, Nestle FO. A role for Th17 cells in the immunopathogenesis of atopic dermatitis? J Invest Dermatol 2008;128:2569-71.   DOI
27 Kee J-Y, Jeon Y-D, Kim D-S, Han Y-H, Park J, Youn D-H, Kim S-J, Ahn KS, Um JY, Hong S-H. Korean red ginseng improves atopic dermatitis-like skin lesions by suppressing expression of proinflammatory cytokines and chemokines in vivo and in vitro. J Ginseng Res 2017;41:134-43.   DOI
28 Bae E-A, Han MJ, Shin Y-W, Kim D-H. Inhibitory effects of Korean red ginseng and its genuine constituents ginsenosides Rg3, Rf, and Rh2 in mouse passive cutaneous anaphylaxis reaction and contact dermatitis models. Biol Pharmaceut Bull 2006;29:1862-7.   DOI
29 Sohn E-H, Jang S-A, Lee C-H, Jang K-H, Kang S-C, Park H-J, Pyo S. Effects of Korean red ginseng extract for the treatment of atopic dermatitis-like skin lesions in mice. J Ginseng Res 2011;35:479-86.   DOI
30 Kawasaki H, Kubo A, Sasaki T, Amagai M. Loss-of-function mutations within the Filaggrin gene and atopic dermatitis.
31 Osawa R, Akiyama M, Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergol Int 2011;60:1-9.   DOI
32 Leung DYM, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 2014;134:769-79.   DOI
33 De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol 2009;129:14-30.   DOI
34 Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol 2016;51:263-92.   DOI
35 Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, Shigematsu Y, Yoshida K, Niizeki H, Motomura K-i, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol 2014;134. 824-830.e826.   DOI
36 Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WHI, Brown SJ, Chen Z, Chen Y, Williams HC. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014;134:818-23.   DOI
37 Suarez AL, Feramisco JD, Koo J, Steinhoff M. Psychoneuroimmunology of psychological stress and atopic dermatitis: pathophysiologic and therapeutic updates. Acta Derm Venereol 2012;92:7-15.   DOI
38 Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, Bergman JN, Chamlin SL, Cohen DE, Cooper KD, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014;71:116-32.   DOI
39 He A, Feldman SR, Fleischer AB. An assessment of the use of antihistamines in the management of atopic dermatitis. J Am Acad Dermatol 2018;79:92-6.   DOI
40 Mooney E, Rademaker M, Dailey R, Daniel BS, Drummond C, Fischer G, Foster R, Grills C, Halbert A, Hill S, et al. Adverse effects of topical corticosteroids in paediatric eczema: australasian consensus statement. Australas J Dermatol 2015;56:241-51.   DOI
41 El-Batawy MMY, Bosseila MAW, Mashaly HM, Hafez VSGA. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci 2009;54:76-87.   DOI
42 Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM, et al. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014;71:327-49.   DOI
43 Taylor K, Swan DJ, Affleck A, Flohr C, Reynolds NJ, Dermatology UKTRNi, the UKDCTN. Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. Br J Dermatol 2017;176:1617-23.   DOI
44 Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001;357:2012-6.   DOI
45 Goujon C, Viguier M, Staumont-Salle D, Bernier C, Guillet G, Lahfa M, Ferrier Le Bouedec M-C, Cambazard F, Bottigioli D, Grande S, et al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a Phase III randomized noninferiority trial. J Allergy Clin Immunol 2018;6. 562-569.e563.   DOI
46 Lee H-H, Song I-H, Friedrich M, Gauliard A, Detert J, Rowert J, Audring H, Kary S, Burmester G-R, Sterry W, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-a antagonists. Br J Dermatol 2007;156:486-91.   DOI
47 Fernandez-Anton Martinez MC, Leis-Dosil V, Alfageme-Roldan F, Paravisini A, Sanchez-Ramon S, Suarez Fernandez R. Omalizumab for the treatment of atopic dermatitis. Actas Dermo-Sifiliograficas (English Edition) 2012;103:624-8.   DOI
48 SimpsonEL, Bieber T,Guttman-Yassky E, Beck LA, Blauvelt A,CorkMJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour J-P, et al. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Eng J Med 2016;375:2335-48.   DOI